BNBX BNB Plus Corp.
USHealthcareAs of 2026-07-10 16:00
Why BNBX matters now
BNB Plus Corp. (BNBX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.38 with -0.13% on the session and $486.7K in market capitalization; recent performance reads 1-month -1.61% and YTD -67.22%.
The latest financial table shown here is Q2 2026, with revenue of $1.0M, net income of $-6.7M, and EPS of $-0.68. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2650.2%.
The latest indexable market news headline is "BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing" from Business Wire.
Additional event context on this page matters because recent insider activity includes KGPLA Holdings LLC filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.31
P/S
0.25
EV/EBITDA
0.01
DCF Value
$-50.33
FCF Yield
-2650.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
43.5%
Operating Margin
-1209.5%
Net Margin
-1646.9%
ROE
-337.1%
ROA
-252.9%
ROIC
-204.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.0M | $-6.7M | $-0.68 |
| Q1 2026 | $565.4K | $-18.6M | $-2.08 |
| Q4 2025 | $199.4K | $-5.3M | $-3.17 |
| FY 2025 | $2.1M | $-15.2M | $-134.23 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.47
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.